The costs and benefits of regulations for reimbursement of new drugs
Author:
Publisher
Elsevier BV
Subject
Health Policy
Reference13 articles.
1. Governmental analysis of the benefits and costs of regulation;Hahn;Journal of Economic Perspectives,1998
2. Andersson F. The international diffusion of new chemical entities. Dissertation. Linköping, Sweden: University of Linköping; 1990.
3. Use of pharmacoeconomics information—report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making;Drummond;Value Health,2003
4. The role of economic evaluation in the pricing and reimbursement of medicines;Drummond;Health Policy,1997
5. Economic evaluation of drugs and its potential uses in policy making;Johannesson;Pharmacoeconomics,1995
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. HTA Barriers for Conditional Approval Drugs;PharmacoEconomics;2023-02-23
2. Healthcare quality and medicine reimbursement criteria in Iran;International Journal of Pharmaceutical and Healthcare Marketing;2017-11-06
3. Barriers to access and use of high cost medicines: A review;Health Policy and Technology;2015-09
4. International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry – a systematic review;Journal of Health Services Research & Policy;2014-08-04
5. A systematic review of coverage decision-making on health technologies—Evidence from the real world;Health Policy;2012-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3